KZR
Kezar Life Sciences Inc
0.175$
+6.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Income Statement
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.0 | -5.4 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 13 | 0.3 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | – | 0.2 | 0.2 | – | – | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.4 | -0.5 | -13 | -0.3 | -0.2 | 6.7 | -0.3 | -0.3 | -0.3 | -0.3 | 0.5 | -0.3 | – | -0.2 | -0.2 | – | – | |
| 7.4 | 1.8 | 1.4 | 1.6 | 1.6 | 3.6 | 5.2 | 4.7 | 4.7 | 5.9 | 6.9 | 7.1 | 7.4 | 7.5 | 7.1 | 8.3 | 8.1 | 9.3 | 9.3 | 11 | 9.8 | 11 | 11 | 14 | 15 | 18 | 21 | 24 | 23 | 17 | 16 | 16 | 16 | 12 | 9.6 | 6.9 | 5.1 | 1.5 | 23 | |
| 8.8 | 0.4 | 0.4 | 0.6 | 0.8 | 1.5 | 1.7 | 1.6 | 1.8 | 2.4 | 2.4 | 2.6 | 2.6 | 3.0 | 2.7 | 3.3 | 3.0 | 3.8 | 3.7 | 4.0 | 4.3 | 4.9 | 5.0 | 5.1 | 5.2 | 6.2 | 5.8 | 8.8 | 5.5 | 6.5 | 5.6 | 5.7 | 5.5 | 5.4 | 5.0 | 4.8 | 3.2 | 5.2 | 18 | |
| 9.0 | 2.3 | 1.9 | 2.2 | 2.4 | 5.1 | 7.0 | 6.3 | 6.4 | 8.3 | 9.4 | 9.7 | 10.0 | 10 | 9.9 | 12 | 11 | 13 | 13 | 14 | 14 | 16 | 16 | 19 | 20 | 25 | 27 | 32 | 28 | 23 | 23 | 22 | 22 | 18 | 15 | 12 | 8.2 | 7.4 | 42 | |
| -9.0 | -2.3 | -1.9 | -2.2 | -2.4 | -5.1 | -7.0 | -6.3 | -6.4 | -8.3 | -9.4 | -9.7 | -10.0 | -10 | -9.9 | -12 | -11 | -13 | -13 | -14 | -14 | -16 | -16 | -19 | -20 | -25 | -27 | -26 | -28 | -24 | -23 | -22 | -22 | -18 | -15 | -12 | -8.3 | -7.4 | -42 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.6 | 0.0 | 0.7 | 0.6 | 0.5 | – | 0.5 | 0.4 | 0.3 | 0.1 | 0.1 | 0.0 | 0.0 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.5 | 0.2 | – | – | |
| -9.0 | -2.3 | -1.9 | -2.1 | -2.3 | -4.9 | -6.8 | -5.7 | -5.8 | -7.6 | -8.7 | -9.1 | -9.6 | -10 | -9.5 | -11 | -11 | -13 | -13 | -14 | -14 | -16 | -16 | -18 | -18 | -22 | -24 | -23 | -32 | -22 | -22 | -20 | -20 | -17 | -14 | -11 | -15 | -5.8 | -45 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | – | – | -0.3 | -0.3 | – | -0.4 | – | -0.4 | – | – | -0.1 | -0.3 | 0.1 | 0.4 | -1.1 | -1.9 | -2.0 | 2.9 | -0.3 | -0.6 | 0.2 | – | – | -0.2 | – | – | – | – | – | – | |
| -9.0 | -2.3 | -1.9 | -2.1 | -2.3 | -4.9 | -6.8 | -5.7 | -5.8 | -7.6 | -8.7 | -9.1 | -9.6 | -10 | -9.5 | -11 | -11 | -13 | -13 | -14 | -14 | -16 | -16 | -18 | -18 | -22 | -24 | -23 | -32 | -22 | -22 | -20 | -20 | -17 | -14 | -11 | -15 | -5.8 | -45 | |
| – | -2.2 | -1.8 | -2.1 | -2.4 | -5.0 | -6.8 | -6.1 | -6.2 | -8.0 | -9.0 | -9.3 | -9.7 | -10 | -9.5 | -11 | -11 | -13 | -13 | -14 | -14 | -15 | -15 | -17 | -18 | -22 | -24 | -22 | -32 | -21 | -21 | -20 | -20 | -16 | -13 | -10 | -8.2 | 0.0 | -32 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.